Some views on risk communication, or why we wrote a book

Pharmacoepidemiology and Drug Safety

Volumn 7, Issue 3, 1998, Pages 213-215

  Urquhart, John ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b AARDEX Group   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; INTERPERSONAL COMMUNICATION; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT;

EID: 0031812396     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199805/06)7:3<213::AID-PDS360>3.0.CO;2-I     Document Type: Article

References (15)

1. Heilmann, K. and Urquhart, J. Keine Angst vor der Angst. Risiko: Element unseres Lebens und Motor des Fortschritts. Kindler Verlag, München, 1983. Urquhart, J. and Heilmann, K. Risk Watch - The Odds of Life. Facts on File, New York & Bicester, UK, 1984. Struijker-Boudier, H. A. J., Heilmann, K. and Urquhart, J. Risiko's Meten. In Den Toren, Baarn, NL, 1985.
2. Heilmann, K. and Urquhart, J. Keine Angst vor der Angst. Risiko: Element unseres Lebens und Motor des Fortschritts. Kindler Verlag, München, 1983. Urquhart, J. and Heilmann, K. Risk Watch - The Odds of Life. Facts on File, New York & Bicester, UK, 1984. Struijker-Boudier, H. A. J., Heilmann, K. and Urquhart, J. Risiko's Meten. In Den Toren, Baarn, NL, 1985.
3. Heilmann, K. and Urquhart, J. Keine Angst vor der Angst. Risiko: Element unseres Lebens und Motor des Fortschritts. Kindler Verlag, München, 1983. Urquhart, J. and Heilmann, K. Risk Watch - The Odds of Life. Facts on File, New York & Bicester, UK, 1984. Struijker-Boudier, H. A. J., Heilmann, K. and Urquhart, J. Risiko's Meten. In Den Toren, Baarn, NL, 1985.
4. Dawson, J. and Henderson, M. Living with Risk - The British Medical Association Guide. Wiley, Chichester, 1987, p. 167.
5. Lord Rothschild. Risk - The Richard Dimbleby Lecture. The Listener, 30 November, 1978.
6. The Lipid Research Clinics Coronary Primary Prevention Trial results: Reduction in incidence of coronary heart disease; (II) The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Journal of the American Medical Association 1984; 251: 351-374.
7. Urquhart, J. Patient compliance as an explanatory variable in four selected cardiovascular studies. In: Compliance in Medical Practice and Clinical Trials. Cramer, J. A. and Spilker, B. (Eds), Raven Press, New York, 1991, pp. 301-322.
8. Urquhart, J. Pharmaco-economics of variable patient compliance with prescribed drug regimens. In: Drug Regimen Compliance - Issues in Clinical Trials and Patient Management. Metry, J.-M. and Mayer, U. A. (Eds). Wiley, Chichester, 1998, in press.
9. McKesson Corp. New Consumer-direct Pharmaceutical Marketing Programs Significantly Prescription Compliance and Coupon Redemption. Press release, 8 January 1998. BW HealthWire.
10. Manninen, V., Elo, M. O., Frick, H., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. Journal of the American Medical Association 1988; 260: 641-651.
11. Cramer, J., Vachon, L., Desforges, C. and Sussman, N. M. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995; 36, 1111-1117.
12. Cox, D. R. Analysing non-compliance in clinical trials. Invited discussion. Statistics in Medicine in press.
13. Efron, B. Foreword to the Limburg Symposium: Analysing non-compliance in clinical trials. Statistics in Medicine in press.
14. Calman, K. C. and Royston, G. H. D. Risk language and dialects. British Medical Journal 1997; 315: 939-942.
15. Spitzer, W. O. Balanced view of risks of oral contraceptives. Lancet 1997; 350: 1566-1567.